Opinion

Video

Addressing Persistent Symptoms in Chronic Spontaneous Urticaria: Beyond IgE-Targeted Treatments

Author(s):

Brian Keegan, MD, PhD,Giselle Mosnaim, MD

Panelists discuss how 30%-50% of patients with chronic spontaneous urticaria remain symptomatic despite treatment, examining the impact of treatment burdens, the limitations of targeting the IgE pathway, and the need for new therapies addressing the IgG pathway.

Video content above is prompted by the following:

  • A significant percentage (30%-50%) of patients are still symptomatic with chronic spontaneous urticaria while on certain recommended doses. What do you believe accounts for this high number of patients who are not responding adequately?
    • Patients have to come in for first 3 doses because this a biologic. Is this preferred? Is there a burden on these patients?
    • Said prescription targets the IgE pathway, but a significant percentage of patients have IgG antibodies as part of their disease pathophysiology. What do you do in your patients who do not respond to this prescription?
    • Why is it imperative to develop new treatments that target the IgG pathway?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Related Content
Asthma lungs. | Image Credit: rashyn- stock.adobe.com
June 25th 2025

Reducing Oral Corticosteroid Dependence in Severe Asthma by Balancing Benefits, Burdens, Path to Safer Care

Cameron Santoro
Reducing the use of oral corticosteroids in patients with severe asthma is a pressing concern due to their associated adverse effects, health care costs, and impact on quality of life.
FDA approval. | Image Credit: aznan - stock.adobe.com
June 20th 2025

FDA Expands Dupilumab Approval as First New Biologic for Bullous Pemphigoid

Cameron Santoro
Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease remission and significantly improving symptoms like itch and disease severity in adults.
Prurigo Nodularis. | Image Credit: this_baker - stock.adobe.com
June 19th 2025

Nemolizumab’s Long-Term Data Reinforce Efficacy, Tolerability in Prurigo Nodularis

Cameron Santoro
Nemolizumab significantly and safely improved itch and skin lesions for up to 2 years in patients with moderate to severe prurigo nodularis.
Ruxolitinib cream. | Image Credit: Ladanifer - stock.adobe.com
June 17th 2025

Topical Ruxolitinib Emerges as Promising Therapy for Diverse Inflammatory Skin Conditions

Cameron Santoro
Topical ruxolitinib cream shows promise as a treatment for inflammatory skin conditions, but lacks consistent data, indicating a need for further research into its use across various dermatologic conditions.
Hidradenitis suppurativa. | Image Credit: Kristina Blokhin - stock.adobe.com
June 16th 2025

Pediatric Hidradenitis Suppurativa Linked to High Prevalence of Chronic Medical, Psychiatric Comorbidities

Cameron Santoro
Pediatric patients with hidradenitis suppurativa have a significantly increased prevalence of chronic medical and psychiatric comorbidities, highlighting the critical need for comprehensive screening and multidisciplinary care.
Chronic urticaria. | Image Credit: Cuoregentile - stock.adobe.com
June 16th 2025

Barzolvolimab Shows Long-Term Efficacy in Chronic Spontaneous Urticaria, Improving Patient Quality of Life

Cameron Santoro
New data shows that barzolvolimab offers sustained complete responses and significantly improved quality of life for patients with chronic spontaneous urticaria, with a favorable safety profile.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo